IDH1/2,   General AML

Koichi Takahashi | ASH 2018 | Clonal heterogeneity of AML and its evolution at relapse

L:

Koichi Takahashi from the MD Anderson Cancer Center discusses two abstracts presented at  60th Annual Society of Hematology Annual Meeting and Exposition, which focused on the clonal evolution of acute myeloid leukemia (AML) during treatment. He highlighted that clonal heterogeneity plays a key role in the relapse from IDH inhibitor treatment. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!